A study released this week in the New England Journal of Medicine concluded that patients receiving the Bayer antibleeding drug, Trasylol, were at a 64% greater risk of death than patients who did not received another medication or no medication at all.
The study, based upon research conducted at Duke University Medical Center. looked at approximately 10,000 patients who had undergone bypass surgery at Duke, and concluded that 6.4 percent of patients who received Trasylol died within 390 days of the surgery. Bayer pulled the medication from the market after a Canadian study was halted because of deaths.
The lawyers at Shipman & Wright, LLP are actively involved in the investigation of cases involving death or serious injury to patients who took Trasylol.